<DOC>
	<DOCNO>NCT00549848</DOCNO>
	<brief_summary>The primary objective study ( TOTXVI ) compare clinical benefit , pharmacokinetics , pharmacodynamics polyethylene glycol-conjugated ( PEG ) asparaginase give high dose ( HD PEG ) versus PEG-asparaginase give conventional dose ( CD PEG ) continuation phase . This study several secondary objective : Therapeutic Objectives : To estimate event-free survival overall survival child ALL treat risk-directed therapy . To study whether intensify induction , include fractionate cyclophosphamide thioguanine , patient day 15 MRD &gt; 5 % , result improve leukemia cytoreduction subgroup compare TOTXV . To assess whether intensification central nervous system ( CNS ) -directed intrathecal systemic chemotherapy improve outcome patient high risk CNS relapse . Exploratory Pharmacologic Objectives : To identify pharmacogenetic , pharmacokinetic pharmacodynamic predictor treatment-related outcome context systemic therapy use protocol . To compare pharmacokinetics pharmacodynamics PEG-asparaginase give high dose ( 3,500 3,000 units/m2 ) versus PEG-asparaginase give conventional dose ( 2,500 units/m2 ) continuation phase . Exploratory Biologic Objectives : To determine prognostic value level minimal residual disease peripheral blood day 8 remission induction . To validate new marker method MRD detection . To genotype natural killer ( NK ) cell receptor measure expression diagnosis reinduction , associate feature treatment outcome . To identify new prognostic factor apply new technology study patient material ( e.g. , stored plasma , serum , cerebrospinal fluid , normal leukemic cell ) . Exploratory Neuroimaging Objectives : To use quantitative MR measure ( Diffusion Tensor Imaging high resolution volumetric image ) ass difference myelin cortical thickness development patient treat ALL relative healthy control match age gender . To assess impact folate pathway genetic polymorphism myelin cortical thickness development neurocognitive performance . To assess impact frontal-parietal lobe myelin cortical thickness development neurocognitive performance attention , work memory , fluency , visual-spatial reasoning processing speed .</brief_summary>
	<brief_title>Total Therapy Study XVI Newly Diagnosed Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Details Treatment Plan : Treatment consist three main phase : Remission Induction , Consolidation , Continuation . 1 . Remission Induction - Intrathecal Treatment Induction Frequency total number triple intrathecal treatment Remission Induction base patient 's risk CNS relapse.All patient receive triple intrathecal treatment day 1 15 . Patients high risk feature may receive additional triple intrathecal treatment day 4 , 8 , 11 , 22. [ ( 1 ; 19 ) /E2A-PBX1 . Induction treatment begin prednisone , vincristine , daunorubicin , PEG-asparaginase triple intrathecal treatment , follow cyclophosphamide plus cytarabine plus thioguanine . Remission Induction Chemotherapy ( 6-7 week ) Prednisone 40 mg/m2/day PO ( divide t.i.d . ) Days 1 - 28 Dexamethasone substitute prednisone patient early T-cell precursor ( ETP ) immunophenotype . Mercaptopurine substitute thiopurine TPMT HET/deficient patient Dexamethasone ( ETP immunophenotype ) 10 mg/m2/day PO ( divide t.i.d . ) Days 1-21 ; 4 mg/m2/day PO ( divide t.i.d ) Days 22-24 ; 2 mg/m2/day PO ( divide t.i.d ) Days 25-28 Vincristine 1.5 mg/m2 IV ( max 2 mg ) Days 1 , 8 , 15 , 22 Daunorubicin 25 mg/m2 IV Days 1 8 PEG-asparaginase 3,000 Units/m2 IV Day 3 - Participants Day 15 MRD great equal 1 % : PEG-asparaginase 3,000 Units/m2 IV Day 15 - Participants Day 15 MRD less 5 % ( exclude MLL positive infant ) : Cyclophosphamide 1000 mg/m2 IV Day 22 Cytarabine 75 mg/m2/dose IV Days 23-26 , 30-33 Thioguanine [ Mercaptopurine ( TPMT HET/deficient patient ) ] 60 mg/m2/dose PO Days 22-35 Dasatinib ( Ph+ participant ) 40 mg/m2 b.i.d start Day 22 induction continue end treatment Day 15 MRD &gt; equal 5 % ( exclude MLL+ infant ) Cyclophosphamide† 300 mg/m2 IV/ q12 hr Days 22-23 Cytarabine 75 mg/m2/dose IV Days 23-26 , 30-33 Thioguanine [ Mercaptopurine ( TPMT HET/deficient patient ) 60 mg/m2/dose PO Days 22-35 Dasatinib‡ ( Ph+ participant ) 40 mg/m2 b.i.d Daily Starting Day 22 induction continue end treatment - Infants MLL positive rearrangement : Clofarabine 40 mg/m2/dose IV Days 22-26 Etoposide 100 mg/m2/dose IV Days 22-26 Cyclophosphamide 300 mg/m2/dose IV Days 22-26 2 . Consolidation Treatment ( 8 week ) High Dose Methotrexate ( HDMTX ) 2.5 gm/ ( low risk ) , target 65 μM ( std/high-risk ) day 1 , 15 , 29 43 . Mercaptopurine 50 mg/m2/day Days 1 56 . All patient receive triple intrathecal therapy every week four dos Days 1 , 15 , 29 , 43 . Dose age dependent . - Reintensification Patients high-risk leukemia may receive reintensification therapy offer option transplant . This treatment attempt maximize leukemic cell kill allogeneic hematopoietic stem cell transplantation . Dexamethasone 20 mg/m2/day PO IV Days 1-6.Cytarabine 2 grams/m2 , 3-hour IV infusion every 12 hour Days 1-2 . Etoposide 100 mg/m2 , 1-hour IV infusion every 12 hour Days 3-5 . Intrathecal methotrexate+hydrocortisone+cytarabine ( ITMHA ) Day 5 ; PEG-asparaginase 3,000 units/m2 IV Day 6 Patients suboptimal response reintensification may receive one two cycle clofarabine/cyclophosphamide/etoposide/dexamethasone : Clofarabine 40 mg/m2/day , 2-hour IV infusion Days 1-5 Etoposide 100 mg/m2/day , 2-hour IV infusion Days 1-5 Cyclophosphamide 300 mg/m2/day , 30-60 minute IV infusion Days 1-5 Dexamethasone 8 mg/m2/day ( divide t.i.d ) Days 1-5 3 . Continuation Treatment ( 120 week ) Abbreviations use : DEX=dexamethasone ; DOX=doxorubicin ; VCR=vincristine ; MP=mercaptopurine ; PEG-ASP=polyethylene glycol-conjugated asparaginase ; MTX=methotrexate ; 6MP=mercaptopurine Weeks 1 20 - treatment depend risk assignment standard-high versus low-risk Week Standard-/High-Risk Low-Risk 1 . DEX+DOX+VCR+MP + PEG-ASP/MP + DEX + VCR 2 . MP MP + MTX 3 . MP + PEG-ASP/MP + MTX 4 . DEX + DOX + VCR + MP/MP + DEX + VCR 5 . MP + PEG-ASP MP + MTX 6 . MP MP + MTX 7 . Reinduction I 8 . Reinduction I 9 . Reinduction I 10 . MP/MP + MTX 11 . DOX + VCR +MP + PEG-ASP/MP + MTX 12 . MP/MP + MTX 13 . MP + PEG-ASP/MP + MTX 14 . DEX + DOX + VCR +6MP/MP + DEX + VCR 15 . MP + PEG-ASP/MP + MTX 16 . MP/MP + MTX 17 . Reinduction II 18 . Reinduction II 19 . Reinduction II 20 . No chemotherapy/MP + MTX Drug Dosages , Schedules Routes Continuation Therapy Weeks 1 6 10 16 : Dexamethasone 12 mg/m2 ( std/high risk ) 8 mg/m2 ( low risk ) PO daily ( divide t.i.d . ) 5 day , Days 1-5 . Doxorubicin 30 mg/m2 IV , Day 1 . Vincristine 2 mg/m2 IV push ( max . 2 mg ) , Day 1 ( 0.05 mg/kg patient &lt; 1 year age &lt; 10kg weight ) . MP ( mercaptopurine ) 50 mg/m2 PO daily 7 day ( std/high risk ) , Days 1-7 , 75 mg/m2 PO daily 7 day ( low risk ) , Days 1-7 . PEG-ASP ( PEG-asparaginase ) 2,500 vs. 3,500 units/m2 IV randomization , Day 1 . Methotrexate 40 mg/m2 IV Day 1 . Dexamethasone , vincristine , asparaginase give regardless blood count , provide patient clinically well . Doxorubicin , mercaptopurine methotrexate hold white blood count ( WBC ) &lt; 1000/mm3 absolute neutrophil count ( ANC ) &lt; 300/mm3 . Doxorubicin , mercaptopurine methotrexate reduce WBC &lt; 1500/mm3 , WBC ANC increase least 2 fold week start date dexamethasone pulse . Reinduction Treatment - This phase treatment part continuation start week 7 17 bone marrow examination confirm complete remission . Doxorubicin HD-cytarabine hold ANC &lt; equal 300/mm3 WBC &lt; 1000/mm3.It preferable start HD-cytarabine WBC &gt; equal 1800/mm3 ANC &gt; 300/mm3 Reinduction treatment give twice : week 7 9 week 17 19 patient . Intrathecal treatment follow leucovorin rescue ( 5 mg/m2/dose PO , max 5 mg ) 24 30 hour patient prior CNS toxicity patient WBC &lt; 1500/mm3 , ANC &lt; 500/mm3 . - Reinduction I Standard/High Risk ALL exclude MLL infant : Dexamethasone 8 mg/m2/day PO ( divide t.i.d . ) Days 1-8 , 15-21 . Vincristine 1.5 mg/m2/week IV . Doxorubicin 30 mg/m2 IV Days 1 , 8 . PEG-asparaginase 3,500 3,500 units/m2 IV Days 1 , 15 . Intrathecal chemotherapy , Methotrexate + hydrocortisone + Ara-C dose age dependent , Day 1 . - Reinduction II Standard/High Risk ALL include MLL infant : Dexamethasone 8 mg/m2/day PO ( t.i.d . ) Days 1-8 , 15-21 . Vincristine 1.5 mg/m2/week IV Days 1 , 8 , 15 . PEG-asparaginase 2,500 3,500 units/m2 IV Days 1 , 15 . High-dose cytarabine 2 gm/m2 IV q 12 hr Days 15 , 16 . Intrathecal chemotherapy , dose age dependent , Day 1 . - Reinduction I Low-Risk ALL : Dexamethasone 8 mg/m2/day PO ( divide t.i.d . ) Days 1-8 , 15-21 . Vincristine 1.5 mg/m2/week IV Days 1 , 8 , 15 . PEG-asparaginase 2,500 3,500 units/m2 IV Days 1 , 15 . D Doxorubicin 30 mg/m2/IV Day 1 . Intrathecal chemotherapy , dose age dependent , Day 1 . - Reinduction II Low-Risk ALL : Dexamethasone 8 mg/m2/day PO ( divide t.i.d . ) Days 1-8 , 15-21 . Vincristine 1.5 mg/m2/week IV Days 1 , 8 , 15 . PEG-asparaginase 2,500 3,500 units/m2 IV Days 1 , 15 . Intrathecal chemotherapy , dose age dependent , Day 1 . - Reinduction I MLL Infants : Dexamethasone 8 mg/m2/day PO ( divide t.i.d . ) Days 1-8 15-21 . Clofarabine 40 mg/m2/day , -hour IV Days 1-5 . Etoposide 100 mg/m2/day , 2-hour IV Days 1-5. cyclophosphamide 300 mg/m2/day , 1-hour IV Days 1-5 . PEG-asparaginase 2,500 3,500 units/m2 IV Days 1 , 15 . Intrathecal chemotherapy , dose age dependent , Day 1 . - Intrathecal Chemotherapy : - Triple intrathecal treatment give low-risk case CNS-1 status ( identifiable blast CSF ) week 7 , 12 , 17 , 25 , 33 , 41 , 49 . - Triple intrathecal treatment give low-risk case CNS-2 , traumatic CSF blast status , WBC &gt; 100 x 109/L week 3 , 7 , 12 , 17 , 25 , 29 , 33 , 37 , 41 , 45 49 . - Triple intrathecal treatment give standard/high-risk case week 7 , 12 , 17 , 25 , 29 , 33 , 37 , 41 , 45 49 . - Triple intrathecal treatment give standard/high-risk case WBC &gt; equal 100 x 109/L , T-cell ALL , ( 1 ; 19 ) /E2A-PBX1 , presence Philadelphia chromosome , MLL rearrangement , hypodiploidy &lt; 44 , CNS-2 CNS-3 status , traumatic lumbar puncture blast week 3 , 7 , 12 , 17 , 25 , 29 , 33 , 37 , 41 , 45 , 49 , 57 , 65 , 73 , 81 , 89 97 Treatment ( week 21 29 ) Week Standard/High Risk Low Risk 21 . MP + PEG-ASP+Dasatinib MP + MTX 22 . MP +Dasatinib MP + MTX 23 . MP + PEG-ASP + Dasatinib MP + MTX 24 . Cyclo + Ara-C + Dasatinib MP + MTX 25 . DEX + VCR + PEG-ASP + Dasatinib MP + DEX + VCR 26 . MP + Dasatinib MP + MTX 27 . MP + PEG-ASP+Dasatinib MP + MTX 28 . Cyclo + Ara-C + Dasatinib MP + MTX 29 . DEX + VCR +PEG-ASP + Dasatinib MP + DEX + VCR Dasatinib Ph+ Treatment ( week 30 end therapy ) Week Standard/High Risk Low Risk 30 . MP + MTX + Dasatinib MP + MTX 31 . MP + MTX + Dasatinib MP + MTX 32 . Cyclo + Ara-C+Dasatinib MP + MTX 33 . DEX + VCR + Dasatinib MP + DEX + VCR 34 . MP + MTX + Dasatinib MP + MTX 35 . MP + MTX + Dasatinib MP + MTX 36 . Cyclo + Ara-C + Dasatinib/MP + MTX 37 . DEX + VCR + Dasatinib /MP + DEX + VCR Dasatinib Ph positive patient Drug Dosages , Schedules Routes Continuation Therapy Week 21 End Therapy : Mercaptopurine 75 mg/m2 PO daily 7 day , Days 1-7 . Methotrexate 40 mg/m2 IV intramuscularly ( IM ) Day 1 . Cyclophosphamide 300 mg/m2 IV , Day 1 . Cytarabine 300 mg/m2 IV , Day 1 . Dexamethasone 12 mg/m2 ( std/high risk ) 8 mg/m2 ( low risk ) PO daily ( divide t.i.d . ) 5 day , Day 1-5 ( week 21 week 68 ) .Decrease dexamethasone 6 mg/m2 PO daily ( divide t.i.d . ) x 5 day , Day 1-5 week 69 week 101 risk group . Vincristine2 mg/m2 IV push ( max 2 mg ) , Day 1 ( 0.05mg/kg patient &lt; 1 year &lt; 10 kg ) . PEG-ASP 2,500 v 3,500 units/m2 IV randomization ( week 30 ) Dexamethasone , vincristine , asparaginase give regardless blood count , provide patient clinically well . Cyclophosphamide , cytarabine , mercaptopurine methotrexate hold WBC &lt; 1000/mm3 ANC &lt; 300/mm3 . Mercaptopurine methotrexate reduce WBC &lt; 1500/mm3 , WBC ANC increase least 2 fold week start date dexamethasone pulse . Doses cyclophosphamide cytarabine may need reduce patient miss 25 % chemotherapy low count deem relate combination . The treatment ( week 30-37 ) repeat total 5 time , week 69 ( see Section 5.5.3 intrathecal therapy ) . After week 69 , patient receive daily mercaptopurine weekly methotrexate interrupt pulse dexamethasone , vincristine , mercaptopurine every 4 week . The dose dexamethasone decrease 6 mg/m2 week 69 week 101 , mercaptopurine methotrexate give . Intrathecal treatment give every 8 week patient risk CNS relapse week 49 discontinue week 97 . Continuation therapy discontinue 120 week . Hematopoietic Stem Cell Transplantation ( patient meet criterion high-risk ALL candidate allogeneic hematopoietic stem cell transplantation ) . However , option decline patient guardian , procedure deem unsuitable attend physician principal investigator , patient remain study continue receive chemotherapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Participant confirm diagnosis precursor Bcell precursor Tcell acute lymphocytic leukemia ( ALL ) immunophenotyping Participant le equal 18 year age Limited prior therapy , include systemic glucocorticoid one week less , one dose vincristine , emergency radiation therapy mediastinum one dose intrathecal chemotherapy . Other circumstance must clear principal investigator ( PI ) coPI . Written , inform consent assent follow Institutional Review Board , NCI , FDA , Office Human Research Protections ( OHRP ) Guidelines . Participants prior therapy , list Pregnant lactate Inability unwillingness research participant legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
</DOC>